Previous 10 | Next 10 |
home / stock / nvo / nvo articles
Britain’s medical costs regulator, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly And Co’s (NY...
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 9.41% on an annualized basis producing an average annual return of 19...
Novo Nordisk A/S (NYSE:NVO) has reportedly filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling p...
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Apple Inc. (NASDAQ:AAPL) is a “buy here.” Apple's iPhone s...
The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous...
Pharmaceutical titan, Novo Nordisk A/S (NYSE:NVO), has had a significant impact on Denmark’s employment landscape, surpassing initial project...
A team of Chinese scientists has successfully cured a patient’s diabetes using cell therapy, marking a global first. What Happened: The patie...
Tesla and SpaceX CEO Elon Musk made a bold prediction about the future cost of Novo Nordisk’s (NYSE:NVO) Ozempic, a popular drug being used ...
Novo Nordisk A/S’s (NYSE:NVO) shared data Friday on its kidney outcomes trial, FLOW. The trial evaluated once-weekly injectable Ozempic fo...
News, Short Squeeze, Breakout and More Instantly...
Novo Nordisk A/S Company Name:
NVO Stock Symbol:
NYSE Market:
2024-06-29 11:34:00 ET For most of its existence, Altimmune (NASDAQ: ALT) has been a little-known biotech aspiring to compete in a world dominated by whales like Novo Nordisk (NYSE: NVO) , the maker of the hit weight loss drug Wegovy and the blockbuster Ozempic for type 2 di...
2024-06-25 10:45:03 ET Regis Corp. (RGS) RGS is trading UP for the last 5 days, and it at trading at $15.94 with volume of 27,015,876 and a one day change of $10.87 (214.86%). Regis Corp. has a 52-week low of 0.31 and a 52-week high of $15.24. The business's 50-day moving average pr...
2024-06-25 10:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for NVO on June 25, 2024 09:00AM ET. The previous analyst recommendation was Outperform. NVO was trading at $146.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...